RECURRENT NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY

Clinical trials for RECURRENT NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY explained in plain language.

Never miss a new study

Get alerted when new RECURRENT NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY trials appear

Sign up with your email to follow new studies for RECURRENT NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New hope for Tough-to-Treat head and neck cancers: can a drug duo outperform the standard?

Disease control Recruiting now

This study is for people with advanced head and neck cancer that has returned or spread and has stopped responding to standard platinum-based chemotherapy. It aims to see if combining two immunotherapy drugs (pembrolizumab and cetuximab) helps patients live longer than using pemb…

Matched conditions: RECURRENT NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY

Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 17, 2026 12:55 UTC

RECURRENT NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY

Get alerted when new RECURRENT NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY trials appear

New hope for Tough-to-Treat head and neck cancers: can a drug duo outperform the standard?